McCandlish John Austin, Feizullayeva Chinara, Spyropoulos Alex C, Cronin Paul P, Naidich Jason J, Brenner Benjamin, McGinn Thomas, Sanelli Pina C, Cohen Stuart L
Imaging Clinical Effectiveness and Outcomes Research, Department of Radiology, Northwell Health, Manhasset, NY; Center for Health Innovations and Outcomes Research, The Feinstein Institutes for Medical Research and The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY; Georgia Institute of Technology, Emory University Hospital, Atlanta, GA.
Imaging Clinical Effectiveness and Outcomes Research, Department of Radiology, Northwell Health, Manhasset, NY; Center for Health Innovations and Outcomes Research, The Feinstein Institutes for Medical Research and The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY.
Chest. 2022 Jun;161(6):1628-1641. doi: 10.1016/j.chest.2021.11.036. Epub 2021 Dec 14.
Pulmonary embolism (PE) remains a leading cause of maternal mortality, yet diagnosis remains challenging. International diagnostic guidelines vary significantly in their recommendations, making it difficult to determine an optimal policy for evaluation.
Which societal-level diagnostic guidelines for evaluation of suspected PE in pregnancy are an optimal policy in terms of its cost-effectiveness?
We constructed a complex Markov decision model to evaluate the cost-effectiveness of each identified societal guidelines for diagnosis of PE in pregnancy. Our model accounted for risk stratification, empiric treatment, diagnostic testing strategies, as well as short- and long-term effects from PE, treatment with low-molecular-weight heparin, and radiation exposure from advanced imaging. We considered clinical and cost outcomes of each guideline from a US health care system perspective with a lifetime horizon. Clinical effectiveness and costs were measured in time-discounted quality-adjusted life years (QALYs) and US dollars, respectively. Strategies were compared using the incremental cost-effectiveness ratio (ICER) with a willingness-to-pay threshold of $100,000/QALY. One-way, multiway, and probabilistic sensitivity analyses were performed.
We identified six international societal-level guidelines. Base-case analysis showed the guideline proposed by the American Thoracic Society and Society of Thoracic Radiology (ATS-STR) yielded the highest health benefits (22.90 QALYs) and was cost-effective, with an ICER of $7,808 over the guidelines proposed by the Australian Society of Thrombosis and Haemostasis and the Society of Obstetric Medicine of Australia and New Zealand (ASTH-SOMANZ). All remaining guidelines were dominated. The ATS-STR guideline-recommended strategy yielded an expected additional 2.7 QALYs/100 patients evaluated over the ASTH-SOMANZ. Conclusions were robust to sensitivity analyses, with the ATS-STR guidelines optimal in 86% of probabilistic sensitivity analysis scenarios.
The ATS-STR guidelines for diagnosis of suspected PE in pregnancy are cost-effective and generate better expected health outcomes than guidelines proposed by other medical societies.
肺栓塞(PE)仍是孕产妇死亡的主要原因,但其诊断仍具有挑战性。国际诊断指南的建议差异很大,难以确定最佳的评估策略。
就成本效益而言,哪种社会层面的孕期疑似PE评估诊断指南是最佳策略?
我们构建了一个复杂的马尔可夫决策模型,以评估每种已确定的社会层面孕期PE诊断指南的成本效益。我们的模型考虑了风险分层、经验性治疗、诊断测试策略,以及PE、低分子肝素治疗和高级成像辐射暴露的短期和长期影响。我们从美国医疗保健系统的角度,以终身视角考虑了每个指南的临床和成本结果。临床有效性和成本分别以时间贴现的质量调整生命年(QALY)和美元来衡量。使用增量成本效益比(ICER)比较策略,支付意愿阈值为100,000美元/QALY。进行了单向、多向和概率敏感性分析。
我们确定了六项国际社会层面的指南。基础病例分析表明,美国胸科学会和胸放射学会(ATS-STR)提出的指南产生了最高的健康效益(22.90 QALY),且具有成本效益,与澳大利亚血栓与止血学会以及澳大利亚和新西兰产科学会(ASTH-SOMANZ)提出的指南相比,ICER为7,808美元。所有其他指南均被主导。与ASTH-SOMANZ相比,ATS-STR指南推荐的策略在每100名接受评估的患者中预期可额外获得2.7个QALY。结论对敏感性分析具有稳健性,在86%的概率敏感性分析场景中,ATS-STR指南是最佳的。
美国胸科学会和胸放射学会关于孕期疑似PE诊断的指南具有成本效益,并且比其他医学学会提出的指南产生更好的预期健康结果。